Ben Derman, Assistant Professor at the University of Chicago, shared a post on X:
“You are not alone in wondering what the implications of the FDA ODAC vote last year are on MRD negativity (and CR) as a surrogate endpoint for clinical trials in myeloma.
I try to piece it together in this approachable primer for ASCO Daily News!”
Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared this post, adding:
“Excellently written ASCO Daily News article by Ben Derman about the nuances of MRD in myeloma.
Including the clearest explanation of surrogate threshold effects I’ve seen – what ‘voltage’ of ∆ MRD neg is needed to predict ∆ PFS/OS?
Hopefully, MRD-guided approvals coming soon!”
More posts featuring Ben Derman and Rahul Banerjee.
